Company Sector
29 companies tagged with Nucleic Acid Drugs.
Nucleic Acid Drugs includes companies developing RNA, DNA, antisense, siRNA, mRNA, or related therapeutic approaches. This category is useful for tracking businesses whose core assets rely on sequence-based medicines rather than traditional small molecules or antibodies.
ALNY
Alnylam Pharmaceuticals is an RNA medicines company focused on gene-silencing therapeutics across rare and specialty diseases. Investors watch platform execution, label expansion, and how new programs broaden the franchise.
APDN
Applied DNA SciencesDNA is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
ARNA
ARNA is an RNA medicines company focused on using nucleic-acid based approaches to address disease at the source. Investors usually watch platform progress, clinical translation, and whether the company can convert molecular science into a broader pipeline.
ATYR
aTyr Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
RNA
Avidity Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
BNTX
BioNTech is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
RNAC
Cartesian Therapeutics is a cell therapy company focused on translating complex living-cell science into clinically meaningful treatments for hard-to-treat diseases. Investors usually watch how the platform converts data, manufacturing readiness, and launch execution into a durable oncology or specialty franchise.
DNAY
Codex DNA is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
LLY
Eli Lilly is a large-cap pharmaceutical company with major exposure to cardiometabolic disease, neuroscience, and oncology. Investors track the stock for commercial scale, label expansion, and a pipeline that still carries meaningful growth optionality.
ETAO
Etao International Group is an RNA medicines company focused on using nucleic-acid based approaches to address disease at the source. Investors usually watch platform progress, clinical translation, and whether the company can convert molecular science into a broader pipeline.
GILD
Gilead Sciences is a large-cap biopharmaceutical company with a commercial base anchored by antivirals and a growing set of oncology and inflammation programs. Investors track the balance between cash flow strength, launch execution, and pipeline replacement.
DNA
GRNA
GreenLight Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
GSK
GSK plc is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
IONS
Ionis Pharmaceuticals is an RNA-targeted medicines company focused on antisense technology and a broad pipeline of genetic and specialty-disease programs. Investors watch platform depth, partner execution, and the pace of new launches.
JNJ
Johnson & Johnson is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
KYTX
Kyverna Therapeutics is an RNA medicines company focused on using nucleic-acid based approaches to address disease at the source. Investors usually watch platform progress, clinical translation, and whether the company can convert molecular science into a broader pipeline.
MDNA
Medicenna Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
MTD
Mettler-Toledo International is an RNA medicines company focused on using nucleic-acid based approaches to address disease at the source. Investors usually watch platform progress, clinical translation, and whether the company can convert molecular science into a broader pipeline.
MRNA
Moderna is an mRNA medicines company that built its platform around vaccine science and is now broadening into infectious disease, oncology, and other therapeutic areas. Investors watch how the company converts platform credibility into a wider commercial story.
NTRA
Natera is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
NVS
Novartis AG is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
ONCT
Oncternal Therapeutics is an RNA medicines company focused on using nucleic-acid based approaches to address disease at the source. Investors usually watch platform progress, clinical translation, and whether the company can convert molecular science into a broader pipeline.
PFE
Pfizer is a global pharmaceutical company with a diversified portfolio across vaccines, internal medicine, oncology, and other specialty areas. Investors track the stock for commercial scale, pipeline renewal, and the pace at which major programs translate into growth.
SRPT
Sarepta Therapeutics is a genetic medicines company focused on neuromuscular disease, with investors watching how its RNA and gene-therapy programs translate into durable clinical and commercial value.
SELB
Selecta is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.
SLN
Silence Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
RNAZ
TransCode Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
VRNA
Verona Pharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
